世界经济论坛-针对性行动和资助亚洲对抗抗菌素耐药性的斗争（英）

Targeted Action and Financing the Fight Against Antimicrobial Resistance in Asia I N S I G H T R E P O R TM A Y 2 0 2 5In collaboration with Centre for Impact Investing and Practices and Philanthropy Asia AllianceImages: Getty ImagesDisclaimer This document is published by the World Economic Forum as a contribution to a project, insight area or interaction. The findings, interpretations and conclusions expressed herein are a result of a collaborative process facilitated and endorsed by the World Economic Forum but whose results do not necessarily represent the views of the World Economic Forum, nor the entirety of its Members, Partners or other stakeholders.© 2025 World Economic Forum. All rights reserved. No part of this publication may be reproduced or transmitted in any form or by any means, including photocopying and recording, or by any information storage and retrieval system.ContentsForeword 3Executive summary 41 The global threat of antimicrobial resistance 51.1 The scale of the crisis 51.2 The background 51.3 Not just a health issue 71.4 Market failures and economic impact 81.5 The impact of climate change 81.6 The global response 92 Asia: The perfect crucible for AMR 112.1 The scale of the problem 112.2 Asia’s rapidly changing demographics 132.3 The factors influencing AMR in Asia 152.4 An urgent call to action 193 Supercharging the fight against superbugs 203.1 Opportunities ripe for capitalizing 20Conclusion 40Contributors 41Endnotes 432Targeted Action and Financing the Fight Against Antimicrobial Resistance in AsiaTargeted Action and Financing the Fight Against Antimicrobial Resistance in AsiaMay 2025Mobilizing the financial resources required to reduce deaths associated with antimicrobial resistance (AMR) around the world could save more than 100 million lives by 2050. In an era of remarkable medical advancement, a silent threat is lurking in our hospitals, homes and communities, turning once-treatable infections into potentially fatal conditions. “Superbugs” – the ominous result of antimicrobial resistance (AMR) – are rapidly evolving to outsmart our most potent antimicrobials. Imagine a world where a simple cut could lead to a life-threatening infection, or where routine surgeries become high-risk gambles with mortality. This is a looming reality that threatens to unravel decades of progress in modern medicine. As these microscopic adversaries continue to adapt and spread, they do not discriminate between victims; however, those in lower-income countries are most at risk. The stark truth is that by 2050, superbugs could claim more lives annually than cancer, with an estimated 10 million deaths per year.1 Equally alarming is the estimated timeline of 10-15 years needed to develop enough new antimicrobial drugs to protect us. The time to act is now, before we find ourselves in a post-antibiotic era where even the most “simple” infections could once again become lethal.This mounting threat carries a significant econom